Solu Therapeutics received FDA Fast Track designation.
The designation is for their lead CyTAC program targeting relapsed or refractory CMML.
Latest Solu Therapeutics News & Updates
See the latest news and media coverage for Solu Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company
solutherapeutics.com- Headquarters
- Boston , United States
- Company type
- Private company
- Number of employees
- 2–25
Last updated
Latest news about Solu Therapeutics
In short: Solu Therapeutics advanced its STX-0712 program for leukemia through FDA Fast Track designation, clinical trials, and $41M in Series A funding.
Company announcements
Solu Therapeutics granted FDA Fast Track designation for STX-0712
The investigational therapy targets chronic myelomonocytic leukemia, an aggressive blood cancer with limited options.
Solu Therapeutics closes $41M Series A and doses first patient
The funding supports clinical evaluation of STX-0712, a novel CCR2-CyTAC therapy for CMML and other hematologic malignancies.
Solu Therapeutics appoints Philip Vickers as President and CEO
He succeeds co-founder David Donabedian and brings over 30 years of biopharma experience to lead development of CyTaC platform.
Media coverage
Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting
BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas...
Solu Therapeutics discovers Nav1.7 and Nav1.8 blockers for pain and more
Solu Therapeutics Inc. has identified heterobifunctional cotinine-containing compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers or sodium channel protein type...
Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic ...
Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial...
Solu Therapeutics Launches with $31 Million to Unlock Cell-Surface Targets
Six years ago, Brandon Turunen, PhD, answered a call from his employer, GSK, for proposals to develop new medicines. "They would oftentimes do calls for...
Never miss news about Solu Therapeutics
Track Solu Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
United Road
Packed Party
Purpose Legal
Allegrow
Sarah Flint
MycRX
Green River
System Surveyor
REED
FreightTrain
Wizard
Ascendant
Fence Supply Inc.
Milam & Greene
SAM
MRP
Greenbridge
Thirteen Lune
EmpowerLocal
Sensorium
WhistlePig
ALM First
Kestrel
Augment
Pegasus
ERG
Hunter Onsite
Tumbleweed Royalty
Supercircle
Silicon Motion
Hamilton
Douglas Emmett